ArticleMedicine2025
Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A prognostic senescence-related long non-coding RNA signature identifies cold and hot tumors of stomach adenocarcinoma.Oncology letters · 2026Article
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is one of the most lethal tumors and is characterized by high mortality and worse prognosis. Long noncoding RNA (lncRNA) plays an important function in tumor formation. Targeting tumor angiogenesis is a crucial cancer treatment strategy. So, this study aims to explore the effects of angiogenesis-related lncRNA (ARlncRNAs) signatures in the prediction of clinical prospects, immunotherapy, and their association with drug sensitivity.
methodsThe Cancer Genome Atlas (TCGA) database was used to get the genetic and clinical information. Co-expression analysis and Cox regression analysis were used to create prognostic profiles. To assess and validate the model's predictive efficacy, principal component analysis, survival analysis, and receiver operating characteristic curves were used. To enhance the model's prediction, a nomogram of forecasts was created, and calibration curves were used. Last, we studied variations in tumor mutational burden, immune-related function, and antiangiogenic medication sensitivity between high- and low-risk cohorts.
resultsWe successfully constructed an angiogenesis-related prognostic signature for LUAD, including 6 lncRNAs (AL157388.1, AL590428.1, LINC02057, AC245041.1, AC068228.1, and AL365181.2). Independent predictive analysis, receiver operating characteristic curve, C-index, and nomogram diagnostic results showed that ARlncRNAs accurately predicted outcome and 1-, 3-, and 5-year overall survival. According to the analysis of the differences in immune-related pathways between high- and low-risk cohorts, the low-risk cohort had a more active immune function. An analysis of immune checkpoints showed that low-risk patients had higher expression of immune checkpoints, which means that low-risk LUAD patients had a more active immune function; these patients may benefit from checkpoint blocking immunotherapy. Screening for sensitive drugs by predicting the IC50 of antivascular drugs, the high-risk cohort has lower IC50 values and is less likely to be resistant than the low-risk cohort.
conclusionOverall, the new predictive features constructed based on ARlncRNAs can effectively predict the outcome of patients and offer a fresh perspective for LUAD diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.